Keith Ward to Lead Little Rock's InterveXion Therapeutics


InterveXion Therapeutics of Little Rock, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, announced Monday the appointment of Keith Ward, Ph.D., to president and CEO.

Want the Full Article?

Get Unlimited Archive Access for $19.95 per Year

Readers must pay to access articles older than 15 days.
Articles newer than 15 days are not included in this offer.

Purchase Now

Already have archive access? Login to view this article.